{
    "name": "trilaciclib",
    "comment": "Rx",
    "other_names": [
        "Cosela"
    ],
    "classes": [
        "Antineoplastics",
        "CDK Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/cosela-trilaciclib-4000134",
    "pregnancy": {
        "common": [
            "Based on mechanism of action, fetal harm may occur when administer to pregnant females",
            "No human or animal data are available ",
            "Advise pregnant females of potential risks to fetus",
            "Pregnancy test recommended in females of reproductive potential"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for at least 3 weeks after final dose"
                ]
            },
            {
                "type": "Infertility ",
                "description": [
                    "No studies performed",
                    "Based on animal studies, fertility may be impaired in females of reproductive potential"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data are available ",
            "Advise to not breastfeed during treatment and for at least 3 weeks after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of serious hypersensitivity to trilaciclib"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis reported with cyclin-dependent kinases (CDK)4/6 inhibitors, including trilaciclib; monitor for symptoms (eg, cough, dyspnea, hypoxia)",
                "May cause fetal harm "
            ],
            "specific": [
                {
                    "type": "Injection-site reactions",
                    "description": [
                        "Injection-site reactions (eg, phlebitis, thrombophlebitis) may occur",
                        "Median time to onset: 15 days (from initiation); 1 day (preceding dose)",
                        "Median duration: 1 day ",
                        "Monitor for signs and symptoms, including infusion-site pain and erythema during infusion"
                    ]
                },
                {
                    "type": "Acute drug hypersensitivity reactions ",
                    "description": [
                        "May cause acute drug hypersensitivity reactions, including facial edema and urticaria",
                        "Median time to onset: 77 days (from initiation); 1 day (preceding dose)",
                        "Median duration: 6 day ",
                        "Monitor for signs and symptoms, including facial, eye, and tongue edema, urticaria, pruritus, and anaphylactic reactions "
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Inhibitor of OCT2, MATE1, MATE-2K ",
                        "Certain OCT2, MATE1, and MATE-2K substrates",
                        "Avoid coadministration ",
                        "Trilaciclib may increase plasma and/or kidney concentrations of certain OCT2, MATE1, and MATE-2K substrates (eg, dofetilide, dalfampridine, cisplatin)",
                        "Even minimal changes in concentrations may lead to serious or life-changing toxicities "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "amantadine",
            "description": {
                "common": "trilaciclib will increase the level or effect of amantadine by  Other (see comment). Avoid or Use Alternate Drug.  Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amiloride",
            "description": {
                "common": "trilaciclib will increase the level or effect of amiloride by  Other (see comment). Avoid or Use Alternate Drug.  Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cimetidine",
            "description": {
                "common": "trilaciclib will decrease the level or effect of cimetidine by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "trilaciclib will decrease the level or effect of ciprofloxacin by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cisplatin",
            "description": {
                "common": "trilaciclib will increase the level or effect of cisplatin by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with cisplatin. Risk of increased cisplatin kidney exposure and altered net accumulation, which may associate with dose-related nephrotoxicity. Closely monitor for nephrotoxicity. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dalfampridine",
            "description": {
                "common": "trilaciclib will increase the level or effect of dalfampridine by  Other (see comment). Avoid or Use Alternate Drug.  Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with dalfampridine. Consider potential benefits of trilaciclib against risk of seizures with increased dalfampridine blood levels."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dofetilide",
            "description": {
                "common": "trilaciclib will decrease the level or effect of dofetilide by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with dofetilide. Consider potential benefits of trilaciclib against risk of QT interval prolongation with increased dofetilide blood levels."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dopamine",
            "description": {
                "common": "trilaciclib will decrease the level or effect of dopamine by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "famotidine",
            "description": {
                "common": "trilaciclib will decrease the level or effect of famotidine by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ganciclovir",
            "description": {
                "common": "trilaciclib will decrease the level or effect of ganciclovir by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "guanidine",
            "description": {
                "common": "trilaciclib will decrease the level or effect of guanidine by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lamivudine",
            "description": {
                "common": "trilaciclib will decrease the level or effect of lamivudine by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "trilaciclib will decrease the level or effect of levofloxacin by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "memantine",
            "description": {
                "common": "trilaciclib will decrease the level or effect of memantine by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metformin",
            "description": {
                "common": "trilaciclib will decrease the level or effect of metformin by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nadolol",
            "description": {
                "common": "trilaciclib will decrease the level or effect of nadolol by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "trilaciclib will decrease the level or effect of oxaliplatin by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pindolol",
            "description": {
                "common": "trilaciclib will decrease the level or effect of pindolol by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pramipexole",
            "description": {
                "common": "trilaciclib will decrease the level or effect of pramipexole by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "procainamide",
            "description": {
                "common": "trilaciclib will decrease the level or effect of procainamide by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ranitidine",
            "description": {
                "common": "trilaciclib will decrease the level or effect of ranitidine by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "relebactam",
            "description": {
                "common": "trilaciclib will decrease the level or effect of relebactam by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "topotecan",
            "description": {
                "common": "trilaciclib will decrease the level or effect of topotecan by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trifluridine/tipiracil",
            "description": {
                "common": "trilaciclib will decrease the level or effect of trifluridine/tipiracil by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trimethoprim",
            "description": {
                "common": "trilaciclib will decrease the level or effect of trimethoprim by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "varenicline",
            "description": {
                "common": "trilaciclib will decrease the level or effect of varenicline by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of trilaciclib (OCT2, MATE1, and MATE-2K inhibitor) with substrates where minimal increased concentration in kidney or blood may lead to serious or life-threatening toxicities. "
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "34"
        },
        {
            "name": "Hypocalcemia",
            "percent": "24"
        },
        {
            "name": "Hypokalemia",
            "percent": "22"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "21"
        },
        {
            "name": "AST increased",
            "percent": "17"
        },
        {
            "name": "Headache",
            "percent": "13"
        },
        {
            "name": "Neutropenia",
            "percent": "32"
        },
        {
            "name": "placebo",
            "percent": "69"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "18"
        },
        {
            "name": "placebo",
            "percent": "33"
        },
        {
            "name": "Anemia",
            "percent": "16"
        },
        {
            "name": "placebo",
            "percent": "34"
        },
        {
            "name": "Rash",
            "percent": "9"
        },
        {
            "name": "Infusion",
            "percent": "8"
        },
        {
            "name": "related reaction",
            "percent": "7"
        },
        {
            "name": "Peripheral edema",
            "percent": "7"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "7"
        },
        {
            "name": "Thrombosis",
            "percent": "6"
        },
        {
            "name": "Hyperglycemia",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "4"
        },
        {
            "name": "H",
            "percent": "7"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "7"
        },
        {
            "name": "Pneumonia",
            "percent": "6"
        },
        {
            "name": "Hypokalemia",
            "percent": "4"
        },
        {
            "name": "Leukopenia",
            "percent": "17"
        },
        {
            "name": "placebo",
            "percent": "3"
        },
        {
            "name": "Fatigue",
            "percent": "3"
        },
        {
            "name": "Thrombosis",
            "percent": "3"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "9"
        },
        {
            "name": "placebo",
            "percent": "3"
        },
        {
            "name": "Hemorrhage",
            "percent": "2"
        },
        {
            "name": "Respiratory failure",
            "percent": "2"
        },
        {
            "name": "Hyperglycemia",
            "percent": "2"
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Cerebrovascular accident",
            "percent": null
        },
        {
            "name": "Ischemic stroke",
            "percent": null
        },
        {
            "name": "Hemoptysis",
            "percent": null
        },
        {
            "name": "Myositis",
            "percent": null
        },
        {
            "name": "Lymphopenia",
            "percent": null
        },
        {
            "name": "Acute respiratory failure",
            "percent": null
        },
        {
            "name": "fatal",
            "percent": null
        }
    ]
}